Randomized Trialhigh evidence

Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial.

Nature medicine·November 8, 2026·PMID 43000472

Why it matters

HFpEF with obesity is common and difficult to treat; this trial provides mechanistic evidence that semaglutide directly reduces cardiac filling pressures, potentially explaining its symptomatic benefits.

Infographic summary of Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled